Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster I

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 807

A Novel Multi-Network Approach Reveals Tissue-Specific Cellular Modulators of Fibrosis in Systemic Sclerosis, Pulmonary Fibrosis and Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 800

An Altered Cardiovascular System Development Gene Expression Signature in Skin is a Hallmark of Limited Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 811

Basophils Are Activated and Stimulate Both B Cells and Fibroblasts in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 799

Biomarker Identification & Molecular Sub-Classification in Systemic Sclerosis for Precision Medicine Using RNA-Seq

9:00AM-11:00AM: Abstract Number: 816

Clinical Response to Treatment with Belimumab and Mycophenolate Mofetil Is Associated with Decrease in B Cell, TGF-β and PDGF Signaling in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 804

Combined-Phenotype Meta-GWAS in Systemic Sclerosis and Rheumatoid Arthritis Identifies IRF4 As a New Common Susceptibility Locus

9:00AM-11:00AM: Abstract Number: 808

Down-Regulation of microRNA-126 in Scleroderma Microvascular Endothelial Cells (MVECs) Is Associated with Impaired Responses to Vascular Endothelial Growth Factor (VEGF) and Defective Angiogenesis

9:00AM-11:00AM: Abstract Number: 820

EZH2 Modulates Angiogenesis and Fibrosis in Scleroderma

9:00AM-11:00AM: Abstract Number: 805

HLA Class II Functional Motifs Associated with Severe Systemic Sclerosis (SSc) and Sclerotic Graft Versus Host Disease (sclGVHD): The Shared Epitopes of Fibrosis

9:00AM-11:00AM: Abstract Number: 813

Identifying and Assessing Subgroups in Systemic Sclerosis Patients Based on Comprehensive Autoantibody Profiling

9:00AM-11:00AM: Abstract Number: 821

IL-31 Is an Inflammatory Pro-Fibrotic Factor Elevated in a Subset of Scleroderma Patients with Severe Pruritus

9:00AM-11:00AM: Abstract Number: 819

Impaired Adiponectin Signaling in SSc Contributes to Myofibroblast Differentiation and Organ Fibrosis

9:00AM-11:00AM: Abstract Number: 810

Microrna-125b As a Potential Anti-Fibrotic and Anti-Apoptotic Regulator in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 809

Micrornas Targeting the Wnt Signalling Pathway in Black African Patients with Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 812

Monocytes/Neurotrophins/Myofibroblasts As a Novel Axis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 803

Multi-Organ RNA-Sequencing of Systemic Sclerosis (SSc) Patients Shows Reproducible Gene Expression Profiles Across Organ Systems

9:00AM-11:00AM: Abstract Number: 801

Multi-Tissue Gene Expression Pathway Analysis of Emerging Therapeutics in a TGFβ Dependent Mouse Model of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 817

RNA and Protein Cargo of Exosomes Isolated from Serum of Systemic Sclerosis Patients Induce a Profibrotic Phenotype in Cultured Normal Human Dermal Fibroblasts: A Potential Mechanism for the Initiation and Progression of a Profibrotic Phenotype in SSc

9:00AM-11:00AM: Abstract Number: 806

Single Cell Rnaseq Defines a Unique Transcriptome Profile for Myofibroblasts in the Skin of Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 815

The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc

9:00AM-11:00AM: Abstract Number: 814

The Regulatory B Cells Ameliorate Skin Sclerosis, Lung Fibrosis, and Autoimmunity Via an Anti-Oxidative Effect in Systemic Sclerosis Model Mice

9:00AM-11:00AM: Abstract Number: 818

The Role of Endothelin 1 in Activation of Vascular Smooth Muscle Cells in Systemic Sclerosis; Increased Cell Proliferation and Resistance to Apoptosis Mediated By Endotehlin B Receptors

9:00AM-11:00AM: Abstract Number: 802

Whole Transcriptome Profiling through RNA Sequencing Reveals Differentially Expressed Sense-Antisense Gene Pairs in Patients with Systemic Sclerosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].